<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35315100</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1096-9071</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>94</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of medical virology</Title>
          <ISOAbbreviation>J Med Virol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Frequency and severity of COVID-19 in patients with various rheumatic diseases treated regularly with colchicine or hydroxychloroquine.</ArticleTitle>
        <Pagination>
          <StartPage>3431</StartPage>
          <EndPage>3437</EndPage>
          <MedlinePgn>3431-3437</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.27731</ELocationID>
        <Abstract>
          <AbstractText>This study aimed to investigate whether patients regularly using colchicine or hydroxychloroquine (HCQ) have an advantage of protection from coronavirus disease 2019 (COVID-19) or developing less severe disease. Patients who were taking colchicine or HCQ regularly for a rheumatic disease including Familial Mediterranean Fever, Behçet's syndrome, Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Sjogren's syndrome, as well as their healthy household contacts as the control group, were included in the study. The clinical data regarding COVID-19 were collected using a standard form, and serum samples were analyzed for anti-severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) nucleocapsid immunoglobulin G (IgG). A total of 635 regular colchicine users with their 643 household contacts and 317 regular HCQ users with their 333 household contacts were analyzed. Anti-SARS-COV-2 IgG was positive in 43 (6.8%) regular colchicine users and 35 (5.4%) household contacts (odds ratio [OR] = 1.3; 95% confidence interval [CI]:0.8-2; p = 0.3). COVID-19-related symptoms were described by 29 (67.4%) of the patients and 17 (48.6%) household contacts (OR = 2.2; 95% CI :0.9-5.5; p = 0.09), and hospital admission was observed in five (11.6%) and one (2.9%) of these subjects (OR = 4.5; 95% CI: 0.5-40.2; p = 0.1), respectively. Seropositive subjects were observed in 22 (6.9%) regular HCQ users and 24 (7.2%) household contacts (OR = 1.1; 95% CI: 0.6-1.9; p =  0.8). COVID-19-related symptoms occurred in 16 (72.7%) of the 22 patients and 12 (50%) of 24 household contacts (OR = 2.7; 95% CI: 0.8-9.1; p = 0.1). Three patients (13.6%) were admitted to hospital, while one household contact (4.2%) was hospitalized (OR = 3.6; 95% CI: 0.3-37.8; p = 0.2). Being on a regular treatment of colchicine or HCQ did not result in the prevention of COVID-19 or amelioration of its manifestations.</AbstractText>
          <CopyrightInformation>© 2022 Wiley Periodicals LLC.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Oztas</LastName>
            <ForeName>Mert</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-4077-1374</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bektas</LastName>
            <ForeName>Murat</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-1788-3837</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Karacan</LastName>
            <ForeName>Ilker</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0003-3100-0866</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biology and Genetics, Istanbul Medeniyet University, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aliyeva</LastName>
            <ForeName>Numune</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0003-2848-4396</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dag</LastName>
            <ForeName>Ayten</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0003-3157-531X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aghamuradov</LastName>
            <ForeName>Sarvan</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-7196-0098</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cevirgen</LastName>
            <ForeName>Selim Berke</ForeName>
            <Initials>SB</Initials>
            <Identifier Source="ORCID">0000-0002-7099-4827</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sari</LastName>
            <ForeName>Selma</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-6839-8164</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bolayirli</LastName>
            <ForeName>Murat</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-5755-7860</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medical Biochemistry, Istanbul University-Cerrahpasa, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Can</LastName>
            <ForeName>Gunay</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0001-5815-6700</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Public Health, Istanbul University-Cerrahpasa, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hatemi</LastName>
            <ForeName>Gulen</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0002-1952-1135</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Seyahi</LastName>
            <ForeName>Emire</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0003-4965-2918</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ozdogan</LastName>
            <ForeName>Huri</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0003-4632-8258</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gul</LastName>
            <ForeName>Ahmet</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0001-8219-3720</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ugurlu</LastName>
            <ForeName>Serdal</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-9561-2282</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Med Virol</MedlineTA>
        <NlmUniqueID>7705876</NlmUniqueID>
        <ISSNLinking>0146-6615</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4QWG6N8QKH</RegistryNumber>
          <NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SML2Y3J35T</RegistryNumber>
          <NameOfSubstance UI="D003078">Colchicine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003078" MajorTopicYN="N">Colchicine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012216" MajorTopicYN="Y">Rheumatic Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Famial Mediterranean fever</Keyword>
        <Keyword MajorTopicYN="N">colchicine</Keyword>
        <Keyword MajorTopicYN="N">covid-19</Keyword>
        <Keyword MajorTopicYN="N">hydroxychloroquine</Keyword>
        <Keyword MajorTopicYN="N">rheumatic and musculoskeletal disease</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>5</Hour>
          <Minute>39</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35315100</ArticleId>
        <ArticleId IdType="pmc">PMC9088463</ArticleId>
        <ArticleId IdType="doi">10.1002/jmv.27731</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497‐506. 10.1016/S0140-6736(20)30183-5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId>
            <ArticleId IdType="pmc">PMC7159299</ArticleId>
            <ArticleId IdType="pubmed">31986264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID‐19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846‐848. 10.1007/s00134-020-05991-x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00134-020-05991-x</ArticleId>
            <ArticleId IdType="pmc">PMC7080116</ArticleId>
            <ArticleId IdType="pubmed">32125452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang W, Zhao Y, Zhang F, et al. The use of anti‐inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID‐19): the perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. 10.1016/j.clim.2020.108393
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clim.2020.108393</ArticleId>
            <ArticleId IdType="pmc">PMC7102614</ArticleId>
            <ArticleId IdType="pubmed">32222466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shi CS, Nabar NR, Huang NN, Kehrl JH. SARS‐coronavirus open reading frame‐8b triggers intracellular stress pathways and activates NLRP3 inflammasomes. Cell Death Discov. 2019;5:101. 10.1038/s41420-019-0181-7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41420-019-0181-7</ArticleId>
            <ArticleId IdType="pmc">PMC6549181</ArticleId>
            <ArticleId IdType="pubmed">31231549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Misawa T, Takahama M, Kozaki T, et al. Microtubule‐driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nature Immunol. 2013;14(5):454‐460. 10.1038/ni.2550
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.2550</ArticleId>
            <ArticleId IdType="pubmed">23502856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ozdogan H, Ugurlu S. Familial mediterranean fever. Presse Med. 2019;48(1 Pt 2):e61‐e76. 10.1016/j.lpm.2018.08.014
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lpm.2018.08.014</ArticleId>
            <ArticleId IdType="pubmed">30686512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. Ann Rheum Dis. 2018;77(6):808‐818. 10.1136/annrheumdis-2018-213225
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2018-213225</ArticleId>
            <ArticleId IdType="pubmed">29625968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155‐166. 10.1038/s41584-020-0372-x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41584-020-0372-x</ArticleId>
            <ArticleId IdType="pubmed">32034323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Clin Infect Dis. 2020;71(15):732‐739. 10.1093/cid/ciaa237
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciaa237</ArticleId>
            <ArticleId IdType="pmc">PMC7108130</ArticleId>
            <ArticleId IdType="pubmed">32150618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in nonhospitalized adults with early COVID‐19: a randomized trial. Ann Intern Med. 2020;173(8):623‐631. 10.7326/M20-4207
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/M20-4207</ArticleId>
            <ArticleId IdType="pmc">PMC7384270</ArticleId>
            <ArticleId IdType="pubmed">32673060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Muench P, Jochum S, Wenderoth V, et al. Development and validation of the Elecsys Anti‐SARS‐CoV‐2 immunoassay as a highly specific tool for determining past exposure to SARS‐CoV‐2. J Clin Microbiol. 2020;58(10):e01694‐20. 10.1128/JCM.01694-20
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JCM.01694-20</ArticleId>
            <ArticleId IdType="pmc">PMC7512151</ArticleId>
            <ArticleId IdType="pubmed">32747400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bourguiba R, Delplanque M, Vinit C, Ackermann F, et al. Clinical course of COVID‐19 in a cohort of 342 familial Mediterranean fever patients with a long‐term treatment by colchicine in a French endemic area. Ann Rheum Dis. 2020. ‐2020‐218707. Advance online publication. 10.1136/annrheumdis-2020-218707
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2020-218707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tardif JC, Bouabdallaoui N, L'Allier PL, et al. Colchicine for community‐treated patients with COVID‐19 (COLCORONA): a phase 3, randomised, double‐blinded, adaptive, placebo‐controlled, multicentre trial. Lancet Respir Med. 2021;9(8):924‐932. 10.1016/S2213-2600(21)00222-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(21)00222-8</ArticleId>
            <ArticleId IdType="pmc">PMC8159193</ArticleId>
            <ArticleId IdType="pubmed">34051877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Topless RK, Gaffo A, Stamp LK, Robinson PC, Dalbeth N, Merriman TR. Gout and the risk of COVID‐19 diagnosis and death in the UK Biobank: a population‐based study. Lancet Rheumatol. 2022; (4):e274–e281(4): e274–e281 10.1016/S2665-9913(21)00401-X
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2665-9913(21)00401-X</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Konig MF, Kim AH, Scheetz MH, et al. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS‐CoV‐2 infection and severe COVID‐19. Ann Rheum Dis. 2020;79(10):1386‐1388. 10.1136/annrheumdis-2020-217690
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2020-217690</ArticleId>
            <ArticleId IdType="pmc">PMC8258626</ArticleId>
            <ArticleId IdType="pubmed">32381561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Conway R, Grimshaw AA, Konig MF, Putman M, et al. COVID‐19 global rheumatology alliance SARS‐CoV‐2 infection and COVID‐19 outcomes in rheumatic disease: a systematic literature review and meta‐analysis. Arthritis Rheumatol. Published online November 22, 2021. 10.1002/art.42030
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.42030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fenwick C, Croxatto A, Coste AT, et al. Changes in SARS‐CoV‐2 spike versus nucleoprotein antibody responses impact the estimates of infections in population‐based seroprevalence studies. J Virol. 2021;95(3):e01828‐20. 10.1128/JVI.01828-20
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.01828-20</ArticleId>
            <ArticleId IdType="pmc">PMC7925109</ArticleId>
            <ArticleId IdType="pubmed">33144321</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35315100</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1096-9071</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>94</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of medical virology</Title>
          <ISOAbbreviation>J Med Virol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Frequency and severity of COVID-19 in patients with various rheumatic diseases treated regularly with colchicine or hydroxychloroquine.</ArticleTitle>
        <Pagination>
          <StartPage>3431</StartPage>
          <EndPage>3437</EndPage>
          <MedlinePgn>3431-3437</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.27731</ELocationID>
        <Abstract>
          <AbstractText>This study aimed to investigate whether patients regularly using colchicine or hydroxychloroquine (HCQ) have an advantage of protection from coronavirus disease 2019 (COVID-19) or developing less severe disease. Patients who were taking colchicine or HCQ regularly for a rheumatic disease including Familial Mediterranean Fever, Behçet's syndrome, Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Sjogren's syndrome, as well as their healthy household contacts as the control group, were included in the study. The clinical data regarding COVID-19 were collected using a standard form, and serum samples were analyzed for anti-severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) nucleocapsid immunoglobulin G (IgG). A total of 635 regular colchicine users with their 643 household contacts and 317 regular HCQ users with their 333 household contacts were analyzed. Anti-SARS-COV-2 IgG was positive in 43 (6.8%) regular colchicine users and 35 (5.4%) household contacts (odds ratio [OR] = 1.3; 95% confidence interval [CI]:0.8-2; p = 0.3). COVID-19-related symptoms were described by 29 (67.4%) of the patients and 17 (48.6%) household contacts (OR = 2.2; 95% CI :0.9-5.5; p = 0.09), and hospital admission was observed in five (11.6%) and one (2.9%) of these subjects (OR = 4.5; 95% CI: 0.5-40.2; p = 0.1), respectively. Seropositive subjects were observed in 22 (6.9%) regular HCQ users and 24 (7.2%) household contacts (OR = 1.1; 95% CI: 0.6-1.9; p =  0.8). COVID-19-related symptoms occurred in 16 (72.7%) of the 22 patients and 12 (50%) of 24 household contacts (OR = 2.7; 95% CI: 0.8-9.1; p = 0.1). Three patients (13.6%) were admitted to hospital, while one household contact (4.2%) was hospitalized (OR = 3.6; 95% CI: 0.3-37.8; p = 0.2). Being on a regular treatment of colchicine or HCQ did not result in the prevention of COVID-19 or amelioration of its manifestations.</AbstractText>
          <CopyrightInformation>© 2022 Wiley Periodicals LLC.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Oztas</LastName>
            <ForeName>Mert</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-4077-1374</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bektas</LastName>
            <ForeName>Murat</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-1788-3837</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Karacan</LastName>
            <ForeName>Ilker</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0003-3100-0866</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biology and Genetics, Istanbul Medeniyet University, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aliyeva</LastName>
            <ForeName>Numune</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0003-2848-4396</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dag</LastName>
            <ForeName>Ayten</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0003-3157-531X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aghamuradov</LastName>
            <ForeName>Sarvan</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-7196-0098</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cevirgen</LastName>
            <ForeName>Selim Berke</ForeName>
            <Initials>SB</Initials>
            <Identifier Source="ORCID">0000-0002-7099-4827</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sari</LastName>
            <ForeName>Selma</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-6839-8164</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bolayirli</LastName>
            <ForeName>Murat</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-5755-7860</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medical Biochemistry, Istanbul University-Cerrahpasa, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Can</LastName>
            <ForeName>Gunay</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0001-5815-6700</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Public Health, Istanbul University-Cerrahpasa, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hatemi</LastName>
            <ForeName>Gulen</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0002-1952-1135</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Seyahi</LastName>
            <ForeName>Emire</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0003-4965-2918</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ozdogan</LastName>
            <ForeName>Huri</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0003-4632-8258</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gul</LastName>
            <ForeName>Ahmet</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0001-8219-3720</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ugurlu</LastName>
            <ForeName>Serdal</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-9561-2282</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Med Virol</MedlineTA>
        <NlmUniqueID>7705876</NlmUniqueID>
        <ISSNLinking>0146-6615</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4QWG6N8QKH</RegistryNumber>
          <NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SML2Y3J35T</RegistryNumber>
          <NameOfSubstance UI="D003078">Colchicine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003078" MajorTopicYN="N">Colchicine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012216" MajorTopicYN="Y">Rheumatic Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Famial Mediterranean fever</Keyword>
        <Keyword MajorTopicYN="N">colchicine</Keyword>
        <Keyword MajorTopicYN="N">covid-19</Keyword>
        <Keyword MajorTopicYN="N">hydroxychloroquine</Keyword>
        <Keyword MajorTopicYN="N">rheumatic and musculoskeletal disease</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>5</Hour>
          <Minute>39</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35315100</ArticleId>
        <ArticleId IdType="pmc">PMC9088463</ArticleId>
        <ArticleId IdType="doi">10.1002/jmv.27731</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497‐506. 10.1016/S0140-6736(20)30183-5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId>
            <ArticleId IdType="pmc">PMC7159299</ArticleId>
            <ArticleId IdType="pubmed">31986264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID‐19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846‐848. 10.1007/s00134-020-05991-x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00134-020-05991-x</ArticleId>
            <ArticleId IdType="pmc">PMC7080116</ArticleId>
            <ArticleId IdType="pubmed">32125452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang W, Zhao Y, Zhang F, et al. The use of anti‐inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID‐19): the perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. 10.1016/j.clim.2020.108393
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clim.2020.108393</ArticleId>
            <ArticleId IdType="pmc">PMC7102614</ArticleId>
            <ArticleId IdType="pubmed">32222466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shi CS, Nabar NR, Huang NN, Kehrl JH. SARS‐coronavirus open reading frame‐8b triggers intracellular stress pathways and activates NLRP3 inflammasomes. Cell Death Discov. 2019;5:101. 10.1038/s41420-019-0181-7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41420-019-0181-7</ArticleId>
            <ArticleId IdType="pmc">PMC6549181</ArticleId>
            <ArticleId IdType="pubmed">31231549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Misawa T, Takahama M, Kozaki T, et al. Microtubule‐driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nature Immunol. 2013;14(5):454‐460. 10.1038/ni.2550
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.2550</ArticleId>
            <ArticleId IdType="pubmed">23502856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ozdogan H, Ugurlu S. Familial mediterranean fever. Presse Med. 2019;48(1 Pt 2):e61‐e76. 10.1016/j.lpm.2018.08.014
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lpm.2018.08.014</ArticleId>
            <ArticleId IdType="pubmed">30686512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. Ann Rheum Dis. 2018;77(6):808‐818. 10.1136/annrheumdis-2018-213225
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2018-213225</ArticleId>
            <ArticleId IdType="pubmed">29625968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155‐166. 10.1038/s41584-020-0372-x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41584-020-0372-x</ArticleId>
            <ArticleId IdType="pubmed">32034323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Clin Infect Dis. 2020;71(15):732‐739. 10.1093/cid/ciaa237
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciaa237</ArticleId>
            <ArticleId IdType="pmc">PMC7108130</ArticleId>
            <ArticleId IdType="pubmed">32150618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in nonhospitalized adults with early COVID‐19: a randomized trial. Ann Intern Med. 2020;173(8):623‐631. 10.7326/M20-4207
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/M20-4207</ArticleId>
            <ArticleId IdType="pmc">PMC7384270</ArticleId>
            <ArticleId IdType="pubmed">32673060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Muench P, Jochum S, Wenderoth V, et al. Development and validation of the Elecsys Anti‐SARS‐CoV‐2 immunoassay as a highly specific tool for determining past exposure to SARS‐CoV‐2. J Clin Microbiol. 2020;58(10):e01694‐20. 10.1128/JCM.01694-20
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JCM.01694-20</ArticleId>
            <ArticleId IdType="pmc">PMC7512151</ArticleId>
            <ArticleId IdType="pubmed">32747400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bourguiba R, Delplanque M, Vinit C, Ackermann F, et al. Clinical course of COVID‐19 in a cohort of 342 familial Mediterranean fever patients with a long‐term treatment by colchicine in a French endemic area. Ann Rheum Dis. 2020. ‐2020‐218707. Advance online publication. 10.1136/annrheumdis-2020-218707
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2020-218707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tardif JC, Bouabdallaoui N, L'Allier PL, et al. Colchicine for community‐treated patients with COVID‐19 (COLCORONA): a phase 3, randomised, double‐blinded, adaptive, placebo‐controlled, multicentre trial. Lancet Respir Med. 2021;9(8):924‐932. 10.1016/S2213-2600(21)00222-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(21)00222-8</ArticleId>
            <ArticleId IdType="pmc">PMC8159193</ArticleId>
            <ArticleId IdType="pubmed">34051877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Topless RK, Gaffo A, Stamp LK, Robinson PC, Dalbeth N, Merriman TR. Gout and the risk of COVID‐19 diagnosis and death in the UK Biobank: a population‐based study. Lancet Rheumatol. 2022; (4):e274–e281(4): e274–e281 10.1016/S2665-9913(21)00401-X
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2665-9913(21)00401-X</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Konig MF, Kim AH, Scheetz MH, et al. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS‐CoV‐2 infection and severe COVID‐19. Ann Rheum Dis. 2020;79(10):1386‐1388. 10.1136/annrheumdis-2020-217690
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2020-217690</ArticleId>
            <ArticleId IdType="pmc">PMC8258626</ArticleId>
            <ArticleId IdType="pubmed">32381561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Conway R, Grimshaw AA, Konig MF, Putman M, et al. COVID‐19 global rheumatology alliance SARS‐CoV‐2 infection and COVID‐19 outcomes in rheumatic disease: a systematic literature review and meta‐analysis. Arthritis Rheumatol. Published online November 22, 2021. 10.1002/art.42030
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.42030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fenwick C, Croxatto A, Coste AT, et al. Changes in SARS‐CoV‐2 spike versus nucleoprotein antibody responses impact the estimates of infections in population‐based seroprevalence studies. J Virol. 2021;95(3):e01828‐20. 10.1128/JVI.01828-20
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.01828-20</ArticleId>
            <ArticleId IdType="pmc">PMC7925109</ArticleId>
            <ArticleId IdType="pubmed">33144321</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
